It is made available under a CC-BY 4.0 International license .

External validation of ultrasound-based models for discrimination between benign and malignant adnexal masses in Italy: the prospective multicenter IOTA phase 6 study

4	Francesca Moro ^{1,2} , Marina Momi ² , Valentina Bertoldo ² , Ashleigh Ledger ³ , Lasai Barreñada ³ , Jolien
5	Ceusters ³ , Davide Sturla ⁴ , Fabio Ghezzi ⁴ , Elisa Mor ⁵ , Letizia Fornari ⁶ , Antonella Vimercati ⁷ ,
6	Saverio Tateo ⁸ , Marianna Roccio ⁹ , Rosalba Giacchello ¹⁰ , Roberta Granese ¹¹ , Daniela Garbin ¹² ,
7	Tiziana De Grandis ¹³ , Federica Piccini ¹⁴ , Patrizia Favaro ¹⁵ , Olga Petruccelli ¹⁶ , Anila Kardhashi ¹⁷ ,
8	Ilaria Pezzani ¹⁸ , Patrizia Ragno ¹⁹ , Laura Falchi ²⁰ , Bruna Anna Virgilio ²¹ , Erika Fruscella ²² , Tiziana
9	Tagliaferri ²³ , Annibale Mazzocco ²⁴ , Floriana Mascilini ² , Francesca Ciccarone ² , Federica Pozzati ² ,
10	Wouter Froyman ^{3,25} , Ben Van Calster ³ , Tom Bourne ²⁶ , Dirk Timmerman ^{3,25} , Giovanni Scambia ² ,
11	*Lil Valentin ^{27, 28} , *Antonia Carla Testa ²

- 12
- 13 ¹ UniCamillus, International Medical University, Rome, Italy
- ² Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- ³ Department of Development and Regeneration, KU Leuven, Leuven, Belgium
- ⁴ Ospedale Filippo del Ponte Ostetricia e Ginecologia, Varese, Lombardia, Italy
- ⁵ Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Lombardia, Italy
- ⁶ Azienda Ospedaliero Universitaria Pisana, Pisa, Toscana, Italy
- ⁷ Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, Puglia, Italy
- 20 ⁸ Ospedale Santa Chiara di Trento, Trento, Trentino-Alto Adige, Italy
- ⁹ Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy
- 22 ¹⁰ ASL CN1, Cuneo, Piemonte, Italy
- 23 ¹¹ Azienda Ospedaliera Universitaria Policlinico "G. MARTINO"
- 24 ¹² Ospedale di Santorso
- 25¹³ IRCCS Candiolo
- 26 ¹⁴ "Ramazzini" di Carpi
- 27 ¹⁵ Ospedale di Bussolengo
- 28 ¹⁶ Azienda Ospedaliera Universitaria O.O.R.R. Foggia
- ¹⁷ Istituto Tumori, IRCCS, "Giovanni Paolo II
- 30 ¹⁸ Presidio Ospedaliero di Treviso
- 31 ¹⁹ ASL AT Asti
- 32 ²⁰ Azienda USL Toscana Centro
- 33 ²¹ Ospedale di Abano Terme
- 34 ²² Ospedale Santo Spirito Roma
- 35 ²³ Ospedale San Maurizio di Bolzano
- 36 ²⁴ Presidio Ospedaliero di Montebelluna, Veneto, Italy
- ²⁵ Department of Obstetrics and Gynecology, University Hospitals KU Leuven, Leuven, Belgium
- 38 ²⁶ Imperial College Healthcare NHS Trust, London, UK
- 39 ²⁷ Skåne University Hospital, Malmö, Sweden
- 40 ²⁸ Department of Clinical Sciences Malmö, Lund University, Sweden

It is made available under a CC-BY 4.0 International license .

41 42	*The last two authors contributed equally to the work.
43	
44	
45	Corresponding authors:
46	Francesca Moro
47	UniCamillus, International Medical University, Rome, Italy
48	Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
49	E-mail: morofrancy@gmail.com; francesca.moro@guest.policlinicogemelli.it;
50	Phone number: +39-3493905802
51	
52	Keywords:
53	Ovarian neoplasm, Ultrasonography,
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	

It is made available under a CC-BY 4.0 International license .

67

68 Abstract

69 Objective To prospectively validate the performance of the Risk of Malignancy Index (RMI), 70 International Ovarian Tumor Analysis (IOTA) Simple Rules Risk Model (SRRisk), IOTA 71 Assessment of Different NEoplasias in the adneXa (ADNEX) and the IOTA two-step strategy in 72 different types of ultrasound centers in Italy.

73 **Methods** This is a multicenter prospective observational study including regional referral centers 74 and district hospitals in Italy. Consecutive patients with an adnexal mass examined with ultrasound 75 by an IOTA certified ultrasound examiner with different levels of experience were included, 76 provided they underwent surgery < 180 days after the inclusion scan. Ultrasound examination was 77 performed transvaginally or transrectally and/or transabdominally based on the characteristics of the 78 women and masses. Reference standard was the histology of the adnexal mass following surgical 79 removal. Discrimination (area under receiver operating characteristic curve, AUROC), calibration, 80 and clinical utility were assessed to illustrate the diagnostic performance of the methods. The 81 performance of the models was also evaluated in predefined subgroups based on menopausal status, 82 type of center (oncology vs non-oncology) and ultrasound examiner's experience: [<500 scans 83 performed, 500-5000 scans performed, >5000 scans performed; European Federation of Societies 84 for Ultrasound in Medicine and Biology (EFSUMB) Level 1, Level 2, Level 3].

85 **Results** 1567 patients were recruited between May 2017 and March 2020 from 23 italian centers. 86 After data cleaning and application of exclusion criteria, our study population consisted of 1431 87 patients in 21 italian centers (10 oncological and 11 non-oncological). Based on histology, 88 995/1431 (69.5%) tumors were benign and 436/1431 (30.5%) were malignant (115/1431, 8.0% 89 borderline, 263/1431, 18.4% primary invasive, 58/1431, 4.1% metastatic tumors). For all IOTA 90 models (SRRisk, ADNEX with and without CA125, two step strategy with and without CA125), 91 the AUROC was between 0.91 (95% CI 0.88-0.93) and 0.92 (0.89-0.94). The AUROC was 0.85 92 (0.81-0.87) for RMI. The malignancy risk was slightly underestimated by all IOTA models, but

It is made available under a CC-BY 4.0 International license .

- 93 least so by SRRisk . All IOTA models had higher net benefit than RMI at risk thresholds from 1%
- by to 50%. AUROC was ≥ 0.90 for all IOTA models in all subgroups, while it ranged from 0.84 to 0.90
- 95 for RMI.
- 96 Conclusions SRRisk, ADNEX and the two step strategy with or without CA125 had similar and 97 good ability to distinguish benign from malignant adnexal tumours in patients examined by either 98 expert or non-expert ultrasound operators in Italy. Their discriminative performance and clinical 99 utility was superior to that of RMI.

It is made available under a CC-BY 4.0 International license .

101 Introduction

Ovarian cancer is the leading cause of death in women diagnosed with gynecological cancers.¹ 102 103 Most ovarian cancers are diagnosed at an advanced stage and require treatment in high volume centers by doctors with expertise in gynecological oncological surgery to optimize outcome.²⁻⁴ 104 105 Correct preoperative characterization of adnexal masses is essential to decide on optimal 106 management: clinical and ultrasound follow-up, surgery in a local center, or referral to an oncology center.^{5,6} Transvaginal ultrasound is the first line method for characterizing adnexal masses. If 107 108 performed by an expert, subjective assessment of the ultrasound images is the optimal method for distinguishing benign from malignant masses.⁷⁻⁹ For less experienced ultrasound examiners there 109 110 are other methods. The Risk of Malignancy Index (RMI) is a scoring system using clinical and 111 ultrasound information that can be used to estimate the likelihood of an ovarian mass being malignant.¹⁰ In some European countries RMI is widely used to triage women with an adnexal mass 112 for referral to an oncological center.^{11–15} The International Ovarian Tumor Analysis (IOTA) group 113 114 has developed several ultrasound based methods that can be used to discriminate between benign and malignant adnexal masses: the Benign Descriptors,^{16,17,} the Simple Rules, ¹⁸ four mathematical 115 116 models to calculate the individual risk of malignancy in an adnexal mass (logistic regression model 117 1, LR1, logistic regression model 2, LR2, the Simple Rules Risk model, SRRisk, and Assessment of Different NEoplasias in the adneXa - ADNEX). ¹⁹⁻²¹ ADNEX is a multinomial regression model 118 119 that calculates the probability of five outcome categories (benign, borderline, stage I primary 120 invasive ovarian malignancy, stage II-IV primary invasive ovarian malignancy, and metastasis from another primary tumor). ²¹ ADNEX can be used with or without CA125 as predictor. ²¹ The IOTA 121 122 group now recommends the IOTA two-step strategy, which means that first the Benign Descriptors are applied, and if these do not apply, ADNEX is used.¹⁷ 123

124 The diagnostic performance of the IOTA methods and of RMI has been validated in prospective 125 and retrospective studies, but most validation studies tested the performance in the hands of

It is made available under a CC-BY 4.0 International license .

experienced ultrasound examiners.^{17,22–32} No prospective study included examiners with little
ultrasound experience and few included examiners with different levels of experience.^{33–35}

The primary aim of this study is to prospectively validate the diagnostic performance of RMI, SRRisk, ADNEX and the IOTA two-step strategy in different types of ultrasound centers in Italy both overall and in relevant subgroups. The secondary aims are to explore the multinomial discrimination performance of ADNEX and the two step strategy, to validate the ability of the Benign Descriptors to correctly classify an adnexal mass as benign, and to validate the classification performance of the Simple Rules and of subjective assessment overall and in the subgroups based on level of ultrasound experience.

135

136 Methods

137 Study design and participants

This is an italian multicenter prospective external validation study of ultrasound based models to discriminate between benign and malignant adnexal masses. The protocol was approved by the Ethical Committee of the Fondazione Policlinico A. Gemelli, IRCCS (PROT 27665/16) and of each participating center (Appendix 1). Written informed consent was obtained from all patients. The study was conducted in accordance with the TRIPOD cluster guidelines.

143

144 *Patients*

145 Consecutive patients with a known or suspected adnexal mass examined with ultrasound by an 146 IOTA certified ultrasound examiner³⁶ and confirmed to have an adnexal mass judged not to be 147 physiological were eligible for inclusion provided they were expected to undergo surgical removal 148 of the mass. The patients were collected between May 2017 and March 2020. Exclusion criteria 149 were: patient's age <18 years, pregnant patients, patients with previous bilateral adnexectomy, 150 patients examined in centers that recruited < 10 patients, only transabdominal ultrasound

It is made available under a CC-BY 4.0 International license .

performed, surgery performed more than 180 days after the ultrasound examination, and denial orwithdrawal of informed consent.

153

154 Data collection

155 Information on age, parity, menopausal status and indication for the ultrasound examination was 156 prospectively collected, as well as information on type of hospital (private practice, local public 157 hospital, regional public hospital, or university hospital), type of center (oncological vs non-158 oncological), and type of ultrasound center (general gynecologic outpatient clinic or specialized 159 ultrasound center). An oncological center was defined as a tertiary referral center with a dedicated 160 gynecological oncology unit. Information on the ultrasound system used, ultrasound examiner's 161 name and level of experience was also recorded. The level of ultrasound experience was based on 162 the number of gynecological scans in non-pregnant women that the examiner had performed at the 163 start of the study. Low experience was defined as <500 scans, intermediate experience as 500-5000 164 scans, and high experience as >5000 scans. We also recorded the level of experience according to 165 the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB level 1, 2 or 3³⁷), and the number of ovarian masses that the operator had examined with ultrasound during 166 167 the preceding year (classified as <50, i.e. <1 per week; 50-200, i.e. up to 4 per week; >200, i.e. >4168 per week).

169

170 Ultrasound examination

A standardized transvaginal (or transrectal if vaginal was not possible) ultrasound examination including color or power Doppler ultrasound examination was performed, supplemented with transabdominal ultrasound if transvaginal or transrectal ultrasound examination was not sufficient. The IOTA examination and measurement technique were used, and the ultrasound findings were described using the IOTA terminology.³⁸ Information on all the variables required for the IOTA Benign Descriptors, Simple Rules, SRRisk, ADNEX and RMI were prospectively collected and

It is made available under a CC-BY 4.0 International license .

177 recorded. Results of subjective assessment were recorded as benign, borderline or malignant. The 178 degree of diagnostic confidence (certainly benign, probably benign, uncertain, probably malignant 179 or probably borderline, certainly malignant or certainly borderline) as well as the specific diagnosis 180 suggested by the ultrasound examiner and chosen from a list of pre-defined diagnoses were also 181 recorded.

If more than one adnexal mass was present, only the one with the most complex ultrasound morphology was included in our statistical analysis. If the ultrasound morphology was similar in all masses, the largest one or the one most easily accessible with ultrasound was used in our statistical calculations. The management was decided by the referring clinician, who took into account clinical symptoms, ultrasound results based on subjective evaluation of the ultrasound images (i.e. those reported in the clinical ultrasound report), and results of other imaging modalities (e.g. computer tomography or magnetic resonance imaging), tumor markers, and patient's preference.

189

190 *Reference standard*

191 Reference standard was the histology of the adnexal mass following surgical removal within 180 192 days after the ultrasound examination by laparotomy or laparoscopy as considered appropriate by 193 the surgeon. Borderline tumors were classified as malignant. The histology of the surgically 194 removed tumor was determined at each local center. Central pathology review was not performed, 195 because we found little differences between local and central pathology reports in a previous IOTA study.¹⁹ Pathologists were blinded to ultrasound predictor variables and model predictions but might 196 197 have received information on the subjective assessment by the ultrasound examiner when clinically 198 relevant. The stage of malignant tumors was recorded using the classification of the International 199 Federation of Gynecology and Obstetrics (FIGO).³⁹

200

201 Data cleaning

It is made available under a CC-BY 4.0 International license .

Data collection was done through the web-based clinical data miner (CDM) software.⁴⁰ Patients automatically received a unique identifier upon enrolment. We encrypted all data communication to ensure data security. A team of statisticians and ultrasound examiners performed data cleaning. Data cleaning included sending queries to participating centers to retrieve missing information or to correct inconsistencies.

207

208 *Prediction models*

We assessed the diagnostic performance of subjective assessment, RMI, Benign Descriptors, Simple rules, SRRisk, ADNEX with and without CA125, and the two-step strategy with and without CA125. Predictions were based on information obtained at the inclusion scan and so are blinded to the outcome. The results of the models were calculated after closing the study and were not used to guide patient managament.

RMI does not give an estimated risk but a non-negative integer (0 or higher), with higher scores suggesting a higher likelihood of malignancy. It includes clinical (CA125 and menopausal status) and ultrasound variables (multilocular cyst, solid areas, bilateral lesions, ascites, abdominal metastases).¹⁰

218 There are four Benign Descriptors, which classify tumors as benign: 1) a unilocular cyst with 219 ground glass echogenicity and largest diameter <10 cm in a premenopausal woman is suggestive of 220 endometrioma (BD 1); 2) a unilocular cyst with mixed echogenicity, acoustic shadows and largest 221 diameter <10 cm in a premenopausal woman is suggestive of benign teratoma (BD 2); 3) a 222 unilocular cyst with anechoic cyst fluid, smooth internal walls and largest diameter <10 cm in a pre-223 or post-menopausal woman is suggestive of a simple cyst or cystadenoma (BD3); 4) all other 224 unilocular cysts with smooth internal walls and largest diameter <10 cm in a pre- or postmenopausal woman (BD 4) are suggestive of a benign cyst.¹⁷ 225

Simple Rules classify tumors as benign, inconclusive, or malignant based on the presence of five
 benign ultrasound features (unilocular cyst, smooth multilocular cyst with largest diameter <100

mm, acoustic shadows, solid component(s) are present but largest diameter is <7 mm, no vascularization on color Doppler) and five malignant ultrasound features (irregular solid tumor, irregular multilocular solid tumor with largest diameter ≥ 100 mm, at least 4 papillary projections, presence of ascites, very strong vascularization on color Doppler). The classification is inconclusive if none of the ten features is present, or if both benign and malignant features are present. ¹⁸ We added inconclusive tumors to those predicted to be malignant, resulting in a binary classifier (benign or malignant).

SRRisk is a logistic regression model that calculates the risk that an adnexal tumor is malignant based on type of center (oncology center vs other center) and on the ten binary ultrasound features used in the Simple Rules. ²⁰

238 ADNEX is a multinomial regression model that calculates the probability of five outcome 239 categories: benign, borderline, stage I primary invasive ovarian malignancy, stage II-IV primary invasive ovarian malignancy, and metastasis from another primary tumor.²¹ One minus the 240 241 probability of a benign tumor equals the estimated risk of malignancy. ADNEX includes three 242 clinical variables (age, type of center, i.e. oncology vs non-oncology center, serum level of CA125) 243 and six ultrasound variables (maximum diameter of the lesion in mm, proportion of solid tissue 244 calculated as the maximum diameter of the largest solid component in mm divided by the maximum 245 diameter of the lesion in mm, presence of more than 10 cyst locules, number of papillary 246 projections, acoustic shadows, ascites). The variable CA125 is optional, but for multinomial 247 discrimination ADNEX works better with than without CA125.²²

The *two-step strategy* uses the Benign Descriptors as a first step. If a Benign Descriptor applies, the mass is classified as benign, if not, ADNEX with or without CA125 is used to estimate the risk of malignancy. ¹⁷ Information about how we estimated the risk of malignancy when a Benign Descriptor applied is found in Appendix 2.

252

253 Statistical analysis and sample size

It is made available under a CC-BY 4.0 International license .

We followed a prespecified statistical analysis plan. The statistical analyses were performed with R version 4.1.2. The adequacy of the sample size is discussed in Appendix 3. We report all performance measures with 95% confidence intervals (CI).

257 Despite it being strongly recommended to collect blood samples for measurement of serum CA125 258 in all patients, CA125 results were missing in some patients. Missing CA125 values were imputed. 259 We performed multiple imputation using the method of fully conditional specification, generating 260 100 imputations, leading to 100 completed datasets. To estimate the missing values of CA125, we 261 used predictive mean matching regression using the outcome and variables that are probably related 262 to either the level of CA125 itself, or to the unavailability of CA125. The multiple imputation 263 procedure is described in Appendix 4. To calculate the predictions for each model, we used the 264 formula present in the original paper.

Results are presented as absolute frequency (percentage) for nominal variables and as median, interquartile range (IQR) and range (min-max) for continuous variables as appropriate. We report the percentage of tumors to which a Benign Descriptor applied and the outcome of masses to which a Benign Descriptor applied (pooled analysis).

We calculated center-specific area under the receiver operating characteristic curve (AUROC) to estimate the ability to discriminate between benign and malignant adnexal masses for RMI and the risk models (SRRisk, ADNEX, IOTA two-step strategy) and used meta-analysis to obtain the overall AUROC per model. The heterogeneity between centers was assessed by calculating 95% prediction intervals (PI). The meta-analysis procedure is described in Appendix 5.

We assessed calibration of the risk models by calculating observed over expected ratio (O:E). O:E is the ratio of the observed risk of having the outcome divided by the risk estimated by the model. An O:E higher than 1 indicates that the model underestimates the risk of malignancy, and an O:E lower than 1 indicates that the model overestimates the risk of malignancy. The ideal value is 1. ^{41,42} We also constructed flexible calibration curves using loess. ⁴³ We calculated center-specific O:E and calibration curves and combined them using meta-analysis. For the meta-analysis of calibration

It is made available under a CC-BY 4.0 International license .

curves, we combined 13 centers with small sample size or low prevalence of malignancy into four
groups to avoid computational problems. The four groups were: Santorso, Foggia, Treviso (group
1); Messina, Carpi, Montebelluna (group 2); Verona, Firenze, Padova, Rome (group 3); and Bari
B, Asti, Bolzano (group 4). The meta-analysis procedure is described in Appendix 5.

284 Clinical utility to decide which patients to refer for specialized oncological care was estimated using decision curve analysis for risk thresholds between 1% and 50%.⁴⁴ Net benefit is a measure 285 286 of clinical utility. To know if a model is clinically useful, we compare it to treat all and treat none 287 (in this case to refer all or to refer none to an oncology center). A model is clinically useful if it is 288 superior to both treat all and treat none. Because RMI does not provide risk estimates, for RMI we 289 computed clinical utility at the following fixed RMI scores: 200 (a threshold often used clinically and recommened in several national guidelines¹¹⁻¹⁵), 250, 100 and 25. We show overall decision 290 291 curves calculated using meta-analysis of center-specific decision curves. The meta-analysis 292 procedure is described in Appendix 5.

293 We calculated sensitivity, specificity, positive predictive value (PPV) and negative predictive value 294 (NPV) for subjective assessment and the Simple Rules (inconclusive cases classified as malignant) 295 and for the risk models at risk of malignancy cut-offs of 1%, 3%, 5%, 10%, 15%, 20%, 25%, 30%, 296 40%, and 50%. For RMI, we report classification performance for cut-offs 25, 100, 200, and 250. 297 We calculated center-specific sensitivity and specificity and combined them using meta-analysis.⁴⁵ 298 Centers with no true positive (TP) and no false positive (FP) test results at a specific threshold were 299 excluded from the meta-analysis of PPV for that threshold. Centers with no true negative (TN) and 300 no false negative (FN) at a specific threshold were excluded from the meta-analysis of NPV for that 301 threshold.

To estimate the multinomial performance of ADNEX and the two-step strategy, we computed the Polytomous Discrimination Index (PDI) and calculated the AUROC for each pair of outcome categories using the conditional risk method.⁴⁶⁻⁴⁷ To evaluate calibration, we computed O:E ratios per category. Due to the small numbers in most centers, we anticipated computational problems

It is made available under a CC-BY 4.0 International license .

306 when attempting to perform meta-analysis for multinomial performance. Therefore, we used the 307 pooled dataset to estimate the multinomial performance of ADNEX and the two-step strategy.

308

309 *Subgroup analyses*

We calculated AUROC and O:E ratio for prespecified subgroups based on menopausal status, type of center (oncology vs non-oncology), and ultrasound examiner's experience (<500 scans performed, 500-5000 scans performed, >5000 scans performed; EFSUMB Level 1, Level 2, and Level 3) using pooled data due to the small numbers in most centers.

314

315 **Results**

316 A total of 1567 patients were recruited from 23 italian centers. After data cleaning and application 317 of exclusion criteria, our study population consisted of 1431 patients in 21 italian centers (10 318 oncological and 11 non-oncological centers) (Figure 1 and Supplementary Table S1). Based on 319 histology, 995/1431 (69.5%) tumors were benign and 436/1431 (30.5%) were malignant (115/1431, 320 8.0% borderline, 263/1431, 18.4% primary invasive, 58/1431, 4.1% metastatic tumors). Tumor 321 outcome according to center is shown in Supplementary Table S1. Clinical, ultrasound and 322 histological characteristics of the study population are summarized in Table 1. Specific histological 323 diagnoses are shown in Supplementary Table S2. The median age of the patients was 52 years (IQR 324 40-62, range 18 to 88), and 745 patients (52%) were postmenopausal. The median of the maximum 325 diameter of the lesion was 69 (IQR 48-100, range 9 - 400) mm, 281 (20%) patients had bilateral 326 masses, and 120 (8%) patients had ascites. CA125 was missing in 28% (394/1431) of patients. The 327 characteristics of our study population and those of the studies in which the RMI and IOTA models 328 were developed are shown in Supplementary Table S3. Patients in our study population were more 329 frequently postmenopausal than those in the development sets of the IOTA models, the Ca125 330 values (when available) were lower, while acoustic shadowing and absent color Doppler signals 331 were more common. Multilocular cysts were less common than in the development data set of the

It is made available under a CC-BY 4.0 International license .

332 Simple Rules, and Ca125 values were higher than in the development data set of RMI. The

333 distribution of tumor outcome (i.e., prevalence of borderline, stage I primary invasive, stage II-IV

334 primary invasive, metastatic tumors) in our study population is reasonably similar to that in the

335 studies in which the IOTA models were developed.

336 The BDs applied to 328/1431 (23%) tumors, of which 325 (99%) were benign, 3/328 (1%, 95% CI

1-2) were borderline, and none was an invasive malignany (Supplementary Table S4).

338 For all IOTA models (ADNEX with and without CA125, SSRisk, two step strategy with and

339 without CA125), the overall AUROC was >0.91, while that of RMI was 0.85 (Figure 2).

340 Differences in AUROC between centers (heterogeneity) were smallest for SRRisk (Figure 2,

341 Supplementary Figure S1-S6).

342 At a risk threshold of 10% (the risk threshold recommended in an international consensus statement for referring patients to an oncology center ⁶), all IOTA models (SRRisk, ADNEX with and without 343 344 Ca125 and the two-step strategy with and without Ca125) had sensitivity >0.9 with specificity 345 ranging from 0.77 to 0.80. ADNEX and the two step strategy had the same classification 346 performance at risk threshold 10%: sensitivity 0.92 and specificity 0.80 when CA125 was included 347 as a predictor, sensitivity 0.94 and specificity 0.77 when CA125 was not included as a predictor 348 (Supplementary Table S5). At a threshold of 200, RMI had sensitivity 0.58 and specificity 0.94 349 (Supplementary Table S6). The Simple Rules were applicable in 1244/1431 (87%) tumors and had 350 sensitivity 0.90 and specificity 0.85 (inconclusive cases classified as malignant). Subjective 351 assessment had sensitivity 0.93 and specificity 0.88 (Supplementary Table S7).

The malignancy risk was slightly underestimated by all IOTA models (O:E ratios 1.04 -1.20) (Table 2). SRRisk was slightly better calibrated than other IOTA models (point estimate O:E ratio 1.04; 95% CI 0.97-1.12) (Table 2, Figure 3). The relation between the RMI score and the observed prevalence of malignancy is shown in supplementary Figure S7. At RMI score 200, the observed prevalence of malignancy was 55% (95% CI 49-61).

It is made available under a CC-BY 4.0 International license .

Decision curves are shown in Figure 4. Irrespective of which RMI cutoff was used, the IOTA methods had higher net benefit than RMI. At risk thresholds lower than 15%, ADNEX and the twostep strategy had the highest net benefit, at risk thresholds above 20% SRRisk and subjective assessment had highest net benefit. RMI at cutoff 200 was less clinically useful than simply treating everyone (referring everyone to an oncology center) at risk thresholds below 15%.

362 The ability of ADNEX and the two-step strategy to discriminate between different tumor types is 363 shown in Table 3 and Supplementary Table S8. The PDI ranged from 0.44 to 0.55 for all four 364 models. ADNEX and the two-step strategy had the same ability to discriminate between the five 365 tumor types. Performance was poorest for discrimination between Stage I primary invasive tumors 366 and metastases (AUROC 0.70 for all four models) and between Stage II-IV primary invasive 367 tumors and metastases (AUROC 0.59 for models without Ca125 and 0.74 for models with CA125). 368 AUROCs ranged from 0.93 to 0.98 for distinguishing benign tumors from invasive malignancies 369 (primary or metastastes). Calibration of the estimated risks for the five tumor types was similar for 370 ADNEX and the two-step strategy irrespective of whether or not CA125 was included as a predictor 371 (Supplementary Table S9). All four models underestimated the risk of borderline, stage I primary 372 invasive, and secondary metastatic tumors (O:E > 1) but overestimated the likelihood of a stage II-373 IV ovarian malignancy and benign tumor (O:E<1).

374

375 Subgroup analyses

Tumor outcome and percentage of missing CA125 values in subgroups according to menopausal status, type of center and ultrasound examiners' level of experience are shown in Table 4. In all subgroups the AUROCs were higher for the IOTA models than for RMI (Figure 5). The AUROCs of the IOTA models were ≥ 0.90 in all subgroups (0.90 – 0.95). They were slightly higher in prethan post-menopausal patients, in non-oncology than oncology centers, and for EFSUMB Level 3 ultrasound examiners than for EFSUMB Level 1 or 2 ultrasound examiners. The sensitivity of subjective assessment was higher for level 3 and level 2 examiners than for level 1 examiners (0.96

It is made available under a CC-BY 4.0 International license .

383 vs 0.92 vs 0.86), but the corresponding specificity was lower (0.84 vs 0.87 vs 0.97) (Supplementary 384 Table S10). The sensitivity of Simple Rules (inconclusive cases classified as malignant) was higher 385 for level 3 than level 2 and 1 examiners (0.95 vs 0.88 vs 0.82) with the corresponding specificity 386 being lower (0.80 vs 0.85 vs 0.92). 387 Calibration of the IOTA models in the subgroups is shown in Supplementary Figure S8. In all 388 subgroups, the malignancy risk tended to be underestimated (point estimate for O:E ratio >1) by the 389 IOTA models, with less underestimation of malignancy risk in postmenopausal than premenopausal 390 patients and in oncology than non-oncology centers. In all subgroups, SRRisk had the least 391 understimation. The 95% CIs for O:E ratios were very wide for EFSUMB level 1 examiners and for 392 examiners that had performed <500 scans at study start due to the small sample size for these 393 groups.

394

- 395 **Discussion**
- 396
- 397 Principal findings

398 SRRisk, ADNEX and the IOTA two-step strategy (with or without CA125) discriminated well 399 between being and malignant adnexal masses and were superior to RMI when validated on a 400 national basis in 21 Italian centers by ultrasound examiners with different levels of ultrasound 401 experience. All IOTA methods had higher net benefit than RMI. SSRisk, ADNEX and the two step-402 strategy (with or without CA125) had the highest net benefit at risk thesholds below 15%.

403

404 *Strengths and limitations*

405 Our study is the first prospective national multicenter study to validate IOTA models and to validate 406 them in the hands of ultrasound examiners with different levels of experience. We assessed the 407 diagnostic performance both in terms of discrimination, calibration and clinical utility. Limitations 408 are the small number of EFSUMB level 1 examiners and examiners that had perfomed <500 scans

409 at the start of the study, the small number of centers from the south of Italy (our aim was to include 410 centers homogenously distributed all over Italy), and that CA125 was missing in a substantial 411 proportion of patients (28%). We adressed the missing CA125 values using multiple imputation. 412 Using histology as reference standard can be seen both as a strength and as a limitation. The 413 strength is that using the same reference standard in all patients avoids differential verification 414 bias. The limitation is that our results might not be applicable to all adnexal masses, which include 415 also those managed with clinical and ultrasound follow-up.

416

417 *Comparison with other studies*

The results of our study agree well with those in other validation studies.^{9,17,23,31,48-52} The 418 419 discriminative performance of ADNEX in our study (AUROC 0.92 and 0.91 for ADNEX with and 420 without CA125, respectively) was similar to that reported in a meta-analysis including 17007 421 adnexal masses examined with ultrasound in different countries and settings in 47 studies (AUROC 0.93 both for ADNEX with and without CA125). ⁴⁸ It was only slightly poorer than that in a large 422 423 international multicenter study conducted by the IOTA group (AUROC 0.94 both for ADNEX with 424 and without CA125) and in a large single center study conducted in a private center in Barcelona, Spain (AUROC 0.95). ^{22,52} The discriminative performance of the two-step stragey was also 425 slightly poorer than in two other large studies ^{17,52} (AUROC 0.92 vs 0.95 when ADNEX with 426 427 CA125 was used as second step test; AUROC 0.91 vs 0.94 vs. 0.95 when ADNEX without CA125 428 was used as second step test). Whether the small differences in discriminative performance are 429 explained by differences in tumor characteristics (the studies cited included also patients managed 430 expectantly) or in ultrasound expertise is difficult to know. We found the discriminative ability and 431 the clinical utility of ADNEX, the two-step strategy and SRRisk to be superior to those of RMI, which agrees with the results of other studies. ^{17,22} Both in our study and in others, the IOTA 432 models underestimated the risk of malignancy, the best calibrated model being SRRisk, and the 433 models being better calibrated in postmenopausal than premenopusal patients. ^{17,22} The Benign 434

It is made available under a CC-BY 4.0 International license .

435 Descriptors were applicable in a lower proportion of patients in our study than in those by Landolfo et al and Pascual et al (23% vs 37% vs 77%).^{17,52} This is explained by the the other two studies 436 437 including also patients managed expectantly and by the study by Pascual et al being an extreme low-risk population.^{17,52} The classification performance of the Simple Rules (inconclusive cases 438 439 classified as malignant) in our study (sensitivity 0.90, specificity 0.85) is reasonably similar to that reported in published meta-analyses (sensitivity and specificity 0.93 and 0.81,⁵⁰ sensitivity and 440 specificity 0.94 and 0.76, ⁵¹ sensitivity and specificity 0.93 and 0.80⁹) and in the international 441 multicenter study by van Calster et al (sensitivity and specificity 0.90 and 0.87^{22}). 442

443 We found the sensitivity of subjective assessment to be 0.93 and the specificity to be 0.88, which is 444 almost identical to the sensitivity and specificity of subjective assessment reported in a metaanalysis (sensitivity 0.93, specificity 0.89).⁹ The classification performance of subjective 445 assessment is heavily dependent on the experience of the ultrasound examiner.⁵³ The performance 446 447 of risk calculation models should be less dependent on ultrasound skill as long as the ultrasound 448 examiner is familiar with the definitions of the variables in the models. Nonetheless, we found some 449 small differences in the discriminative and calibration performance of the IOTA models between 450 examiners with different levels of experience, with performance being slightly better in the group of 451 EFSUMB level 3 examiners. However, it is difficult to interpret these differences, because they 452 may be explained by a difference in tumor types between the groups.

453

454 *Implications in clinical practice*

The good performance of the IOTA models in our study, which includes also ultrasound examiners with little ultrasound experience and both local, regional and university hospitals, supports that IOTA models can be widely applied in clinical practice. Our findings also support the recommendation by Landolfo et. al ¹⁷ to use the two-step strategy. The two-step strategy had almost the same discrimination and calibration performance and almost the same clinical utility as ADNEX at risk thresholds up to 20% (and better clinical utility than ADNEX at the lowest risk thresholds) in

It is made available under a CC-BY 4.0 International license .

461	our study, but the two-step strategy is easier to use than ADNEX while still offering the advantage					
462	of providing an estimate of the likelihood of four types of malignancy.					
463						
464	Future perspectives					
465	Prospective studies including a very large number of ultrasound examiners with limited experience					
466	are needed to confirm our results. It would be important to investigate the effect of using the IOTA					
467	models in impact studies. ⁵⁴ Such studies will show whether use of IOTA models in daily practice					
468	improve decision making and, ultimately, patient outcome.					
469						
470	Conclusions					
471	SRRisk, ADNEX and the two step strategy with or without CA125 had similar and good ability to					
472	distinguish benign from malignant adnexal tumours in patients examined by either expert or non-					
473	expert ultrasound operators in Italy, and they were all superior to RMI. Our results support the					
474	recommendation by the IOTA-group to use the two-step strategy to characterize ovarian tumors.					
475						
476						
477	References					
478 479 480	1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi: 10.3322/caac.21820.					
481 482 483	 Woo YL, Kyrgiou M, Bryant A, Everett T, Dickinson HO. Centralisation of services for gynaecological cancers - a Cochrane systematic review. <i>Gynecol Oncol.</i> 2012;126(2):286- 90. doi: 10.1016/j.ygyno.2012.04.012. 					
484 485 486 487	 Engelen MJ, Kos HE, Willemse PH, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. <i>Cancer</i>. 2006;106(3):589-98. doi: 10.1002/cncr.21616. 					
488 489 490 491	4. Vernooij F, Heintz AP, Witteveen PO, van der Heiden-van der Loo M, Coebergh JW, van der Graaf Y. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study. <i>J Natl Cancer Inst.</i> 2008;100(6):399-406. doi:					

10.1093/jnci/djn033.

It is made available under a CC-BY 4.0 International license .

493		
494	5.	Froyman W, Landolfo C, De Cock B, et al. Risk of complications in patients with
495		conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a
496		multicentre, prospective, cohort study. Lancet Oncol. 2019;20(3):448-458. doi:
497		10.1016/S1470-2045(18)30837-4.
498		
499	6.	Timmerman D, Planchamp F, Bourne T, et al. ESGO/ISUOG/IOTA/ESGE Consensus
500		Statement on preoperative diagnosis of ovarian tumors. Ultrasound Obstet Gynecol.
501		2021;58(1):148-168. doi: 10.1002/uog.23635.
502		
503	7.	Valentin L, Hagen B, Tingulstad S, Eik-Nes S. Comparison of 'pattern recognition' and
504		logistic regression models for discrimination between benign and malignant pelvic masses: a
505		prospective cross validation. Ultrasound Obstet Gynecol. 2001;18(4):357-65. doi:
506		10.1046/j.0960-7692.2001.00500.x.
507		5
508	8.	Timmerman D. The use of mathematical models to evaluate pelvic masses; can they beat an
509		expert operator? Best Pract Res Clin Obstet Gynaecol. 2004;18(1):91-104. doi:
510		10.1016/j.bpobgyn.2003.09.009.
511		
512	9.	Meys EM, Kaijser J, Kruitwagen RF, et al. Subjective assessment versus ultrasound models
513		to diagnose ovarian cancer: A systematic review and meta-analysis. Eur J Cancer. 2016
514		May;58:17-29. doi: 10.1016/j.ejca.2016.01.007.
515		
516	10	Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy
516 517	10	Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative
516 517 518	10	Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i> . 1990;97(10):922-9. doi: 10.1111/j.1471-
516 517 518 519	10	Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i> . 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x.
516 517 518 519 520	10	Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i> . 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x.
516 517 518 519 520 521	10	 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i>. 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x. <u>https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-</u>
516 517 518 519 520 521 522	10	. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i> . 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x. <u>https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/</u>
516 517 518 519 520 521 522 522 523	10	 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i>. 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x. <u>https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/</u>
516 517 518 519 520 521 522 523 524	10.	 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i>. 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x. <u>https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/</u> <u>https://www.legeforeningen.no/contentassets/75de8a48892f4cdc8db45fc7804d369c/benigne</u>
516 517 518 519 520 521 522 523 524 525	10. 11. 12.	 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i>. 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x. <u>https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/</u> <u>https://www.legeforeningen.no/contentassets/75de8a48892f4cdc8db45fc7804d369c/benigne-ovarialcyster_2024.pdf</u>
516 517 518 519 520 521 522 523 524 525 526	10 11 12	 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i>. 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x. <u>https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/</u> <u>https://www.legeforeningen.no/contentassets/75de8a48892f4cdc8db45fc7804d369c/benigne-ovarialcyster_2024.pdf</u>
516 517 518 519 520 521 522 523 524 525 526 527	10 11 12 13	 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i>. 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x. <u>https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/</u> <u>https://www.legeforeningen.no/contentassets/75de8a48892f4cdc8db45fc7804d369c/benigne-ovarialcyster_2024.pdf</u> <u>https://static1.squarespace.com/static/5467abcce4b056d72594db79/t/58ed3a3ddb29d654c6c</u>
516 517 518 519 520 521 522 523 524 525 526 527 528	10 11 12 13	 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i>. 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x. <u>https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/</u> <u>https://www.legeforeningen.no/contentassets/75de8a48892f4cdc8db45fc7804d369c/benigne-ovarialcyster_2024.pdf</u> <u>https://static1.squarespace.com/static/5467abcce4b056d72594db79/t/58ed3a3ddb29d654c6c_d634c/1491941952677/Cysteguideline.pdf</u>.
516 517 518 519 520 521 522 523 524 525 526 527 528 529	10 11 12 13	 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i>. 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x. <u>https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/</u> <u>https://www.legeforeningen.no/contentassets/75de8a48892f4cdc8db45fc7804d369c/benigne-ovarialcyster_2024.pdf</u> <u>https://static1.squarespace.com/static/5467abcce4b056d72594db79/t/58ed3a3ddb29d654c6c_d634c/1491941952677/Cysteguideline.pdf</u>.
516 517 518 519 520 521 522 523 524 525 526 527 528 529 530	10 11 12 13	 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i>. 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x. <u>https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/</u> <u>https://www.legeforeningen.no/contentassets/75de8a48892f4cdc8db45fc7804d369c/benigne-ovarialcyster_2024.pdf</u> <u>https://static1.squarespace.com/static/5467abcce4b056d72594db79/t/58ed3a3ddb29d654c6c_d634c/1491941952677/Cysteguideline.pdf</u>. Royal College of Obstetricians and Gynaecologists. The Management of Ovarian Cysts in
516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531	10 11 12 13 14	 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i>. 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x. https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/ https://www.legeforeningen.no/contentassets/75de8a48892f4cdc8db45fc7804d369c/benigne -ovarialcyster_2024.pdf https://static1.squarespace.com/static/5467abcce4b056d72594db79/t/58ed3a3ddb29d654c6c d634c/1491941952677/Cysteguideline.pdf. Royal College of Obstetricians and Gynaecologists. The Management of Ovarian Cysts in Postmenopausal Women. Green-top Guideline No. 34. July 2016.
516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532	10 11 12 13 14	 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i>. 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x. https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/ https://www.legeforeningen.no/contentassets/75de8a48892f4cdc8db45fc7804d369c/benigne -ovarialcyster_2024.pdf https://static1.squarespace.com/static/5467abcce4b056d72594db79/t/58ed3a3ddb29d654c6c d634c/1491941952677/Cysteguideline.pdf. Royal College of Obstetricians and Gynaecologists. The Management of Ovarian Cysts in Postmenopausal Women. Green-top Guideline No. 34. July 2016.
516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533	10 11 12 13 14 15	 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i>. 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x. https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/ https://www.legeforeningen.no/contentassets/75de8a48892f4cdc8db45fc7804d369c/benigne-ovarialcyster_2024.pdf https://static1.squarespace.com/static/5467abcce4b056d72594db79/t/58ed3a3ddb29d654c6cd634c/1491941952677/Cysteguideline.pdf. Royal College of Obstetricians and Gynaecologists. The Management of Ovarian Cysts in Postmenopausal Women. Green-top Guideline No. 34. July 2016. Sundar S, Agarwal R, Davenport C, et al. Risk-prediction models in postmenopausal
516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534	10. 11. 12. 13. 14. 15.	 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i>. 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x. https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/ https://www.legeforeningen.no/contentassets/75de8a48892f4cdc8db45fc7804d369c/benigne-ovarialcyster_2024.pdf https://static1.squarespace.com/static/5467abcce4b056d72594db79/t/58ed3a3ddb29d654c6cd634c/1491941952677/Cysteguideline.pdf. Royal College of Obstetricians and Gynaecologists. The Management of Ovarian Cysts in Postmenopausal Women. Green-top Guideline No. 34. July 2016. Sundar S, Agarwal R, Davenport C, et al. Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre,
516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535	10 11 12 13 14 15	 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol.</i> 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x. https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/ https://www.legeforeningen.no/contentassets/75de8a48892f4cdc8db45fc7804d369c/benigne-ovarialcyster_2024.pdf https://static1.squarespace.com/static/5467abcce4b056d72594db79/t/58ed3a3ddb29d654c6cd634c/1491941952677/Cysteguideline.pdf. Royal College of Obstetricians and Gynaecologists. The Management of Ovarian Cysts in Postmenopausal Women. Green-top Guideline No. 34. July 2016. Sundar S, Agarwal R, Davenport C, et al. Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study. Lancet Oncol. 2024 Oct;25(10):1371-1386. doi:
516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536	10 11 12 13 14 15	 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <i>Br J Obstet Gynaecol</i>. 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x. <u>https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/</u> <u>https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/</u> <u>https://static1.squarespace.com/static/5467abcce4b056d72594db79/t/58ed3a3ddb29d654c6cd634c/1491941952677/Cysteguideline.pdf</u>. Royal College of Obstetricians and Gynaecologists. The Management of Ovarian Cysts in Postmenopausal Women. Green-top Guideline No. 34. July 2016. Sundar S, Agarwal R, Davenport C, et al. Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study. Lancet Oncol. 2024 Oct;25(10):1371-1386. doi: 10.1016/S1470-2045(24)00406-6.

538 16. Ameye L, Timmerman D, Valentin L, et al. Clinically oriented three-step strategy for
539 assessment of adnexal pathology. *Ultrasound Obstet Gynecol*. 2012;40(5):582-91. doi:
540 10.1002/uog.11177.

- 542 17. Landolfo C, Bourne T, Froyman W, et al. Benign descriptors and ADNEX in two-step
 543 strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5
 544 multicenter cohort. *Ultrasound Obstet Gynecol.* 2023 Feb;61(2):231-242. doi:
 545 10.1002/uog.26080.
- 547 18. Timmerman D, Testa AC, Bourne T, et al. Simple ultrasound-based rules for the diagnosis
 548 of ovarian cancer. *Ultrasound Obstet Gynecol*. 2008;31(6):681-90. doi: 10.1002/uog.5365.
- 19. Timmerman D, Testa AC, Bourne T, et al. Logistic regression model to distinguish between
 the benign and malignant adnexal mass before surgery: a multicenter study by the
 International Ovarian Tumor Analysis Group. *J Clin Oncol.* 2005;23(34):8794-801. doi:
 10.1200/JCO.2005.01.7632.
- Timmerman D, Van Calster B, Testa A, et al. Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group.
 Am J Obstet Gynecol. 2016;214(4):424-437. doi: 10.1016/j.ajog.2016.01.007.
 - 21. Van Calster B, Van Hoorde K, Valentin L, et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. *BMJ*. 2014;349:g5920. doi: 10.1136/bmj.g5920.
 - 22. Van Calster B, Valentin L, Froyman W, et al. Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort study. *BMJ*. 2020;370:m2614. doi: 10.1136/bmj.m2614.
 - 23. Hiett AK, Sonek JD, Guy M, Reid TJ. Performance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O-RADS in differentiating between benign and malignant adnexal lesions in North American women. *Ultrasound Obstet Gynecol*. 2022;59(5):668-676. doi: 10.1002/uog.24777.
 - 24. Jeong SY, Park BK, Lee YY, Kim TJ. Validation of IOTA-ADNEX Model in Discriminating Characteristics of Adnexal Masses: A Comparison with Subjective Assessment. *J Clin Med.* 2020;9(6):2010. doi: 10.3390/jcm9062010.
- 577 25. Esquivel Villabona AL, Rodríguez JN, Ayala N, et al. Two-Step Strategy for Optimizing the
 578 Preoperative Classification of Adnexal Masses in a University Hospital, Using International
 579 Ovarian Tumor Analysis Models: Simple Rules and Assessment of Different NEoplasias in
 580 the adneXa Model. *J Ultrasound Med.* 2022;41(2):471-482. doi: 10.1002/jum.15728.
- 26. Rashmi N, Singh S, Begum J, Sable MN. Diagnostic Performance of Ultrasound-Based
 International Ovarian Tumor Analysis Simple Rules and Assessment of Different

It is made available under a CC-BY 4.0 International license .

584 585 586	NEoplasias in the adneXa Model for Predicting Malignancy in Women with Ovarian Tumors: A Prospective Cohort Study. <i>Womens Health Rep</i> (New Rochelle). 2023;4(1):202-210. doi: 10.1089/whr.2022.0072.
587 588 589 590	27. Velayo CL, Reforma KN, Sicam RVG, Diwa MH, Sy ADR, Tantengco OAG. Diagnostic Performances of Ultrasound-Based Models for Predicting Malignancy in Patients with Adnexal Masses. <i>Healthcare</i> (Basel). 2022;11(1):8. doi: 10.3390/healthcare11010008.
592 593 594 595	28. Qian L, Du Q, Jiang M, Yuan F, Chen H, Feng W. Comparison of the Diagnostic Performances of Ultrasound-Based Models for Predicting Malignancy in Patients With Adnexal Masses. <i>Front Oncol.</i> 2021;11:673722. doi: 10.3389/fonc.2021.673722.
596 597 598	29. Araujo KG, Jales RM, Pereira PN, et al. Performance of the IOTA ADNEX model in preoperative discrimination of adnexal masses in a gynecological oncology center. <i>Ultrasound Obstet Gynecol.</i> 2017;49(6):778-783. doi: 10.1002/uog.15963.
600 601 602 603	30. Timmerman D, Van Calster B, Testa AC, et al. Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group. <i>Ultrasound Obstet Gynecol.</i> 2010;36(2):226-34. doi: 10.1002/uog.7636.
603 604 605 606	31. Timmerman D, Ameye L, Fischerova D, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. <i>BMJ</i> . 2010;341:c6839. doi: 10.1136/bmj.c6839.
608 609 610	32. Sayasneh A, Ferrara L, De Cock B, et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model: a multicentre external validation study. <i>Br J Cancer</i> . 2016;115(5):542-8. doi: 10.1038/bjc.2016.227.
612 613 614	33. Poonyakanok V, Tanmahasamut P, Jaishuen A, et al. Preoperative Evaluation of the ADNEX Model for the Prediction of the Ovarian Cancer Risk of Adnexal Masses at Siriraj Hospital. <i>Gynecol Obstet Invest.</i> 2021;86(1-2):132-138. doi: 10.1159/000513517.
615 616 617 618 619 620	34. Giourga M, Pouliakis A, Vlastarakos P, et al. Evaluation of IOTA-ADNEX Model and Simple Rules for Identifying Adnexal Masses by Operators with Varying Levels of Expertise: A Single-Center Diagnostic Accuracy Study. Ultrasound Int Open. 2023;9(1):E11-E17. doi: 10.1055/a-2044-2855.
620 621 622 623 624 625	35. Grover SB, Patra S, Grover H, Mittal P, Khanna G. Prospective revalidation of IOTA "two- step", "alternative two-step" and "three-step" strategies for characterization of adnexal masses - An Indian study focussing the radiology context. <i>Indian J Radiol Imaging</i> . 2020;30(3):304-318. doi: 10.4103/ijri.IJRI_279_20.
626 627	36. <u>https://iotaplus.org/en/certified-members</u> .
627 628 629	37. European Federation of Societies for Ultrasound in Medicine and Biology. <i>Ultraschall Med</i> 2006;27(1): 79-95 doi: 10.1055/s-2006-933605

It is made available under a CC-BY 4.0 International license .

630	
631	38. Timmerman D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I; International
632	Ovarian Tumor Analysis (IOTA) Group. Terms, definitions and measurements to describe
633	the sonographic features of adnexal tumors: a consensus opinion from the International
634	Ovarian Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol. 2000;16(5):500-5.
635	
636 637	39. Prat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the
629	10 1016/i ii an $2012 10 001$
038	10.1010/J.IJg0.2015.10.001.
640	40 Installé AI Van den Bosch T. De Moor P. Timmermen D. Clinical data miner: an electronic
641	40. Instance AJ, van den Bosen 1, De Woor B, Timmerman D. Climical data minier, an electronic
642	case report form system with integrated data preprocessing and machine-rearing noraries
642	supporting clinical diagnostic model research. JMIR Mea Inform. 2014;2(2):e28. doi:
643	10.2196/medinform.3251.
644 645	41 Riley RD Debray TPA Collins GS et al. Minimum sample size for external validation of a
6/6	clinical prediction model with a binary outcome Stat Med 2021:40(19):4230-4251 doi:
647	10 1002/sim 9025
6/8	10.1002/300.9025.
649	42 Debray TP Damen IA Snell KI et al. A guide to systematic review and meta-analysis of
650	prediction model performance <i>BML</i> 2017:356:i6460 doi: 10.1136/bmi.i6460
651	prediction model performance. <i>BMJ</i> . 2017,350.10400. doi: 10.1150/011J.10400.
652	43 Van Calster B Nieboer D Vergouwe Y De Cock B Pencina MI Steverberg EW A
653	calibration hierarchy for risk models was defined: from utonia to empirical data <i>I Clin</i>
654	<i>Enidemial</i> 2016:74:167-76 doi: 10.1016/i.iclineni.2015.12.005
655	<i>Epidemiol.</i> 2010,74.107-70. doi: 10.1010/J.Jennepi.2015.12.005.
656	44 Vickers AI Elkin EB Decision curve analysis: a novel method for evaluating prediction
657	models Med Decis Making 2006:26(6):565-74 doi: 10.1177/0272989X06295361
658	
659	45. Lin L. Chu H. Meta-analysis of Proportions Using Generalized Linear Mixed Models.
660	<i>Epidemiology</i> . 2020;31(5):713-717. doi: 10.1097/EDE.00000000001232.
661	
662	46. Van Calster B, Vergouwe Y, Looman CW, Van Belle V, Timmerman D, Steverberg EW.
663	Assessing the discriminative ability of risk models for more than two outcome categories.
664	<i>Eur J Epidemiol.</i> 2012:27(10):761-70. doi: 10.1007/s10654-012-9733-3.
665	
666	47. Van Calster B, Van Belle V, Vergouwe Y, Timmerman D, Van Huffel S, Steverberg EW.
667	Extending the c-statistic to nominal polytomous outcomes: the Polytomous Discrimination
668	Index Stat Med 2012:31(23):2610-26 doi: 10.1002/sim 5321
669	index. <i>bitti inter.</i> 2012, 51(25):2010-20. doi: 10.1002/5iiii.5521.
670	48. Barreñada L, Ledger A, Dhiman P, et al. ADNEX risk prediction model for diagnosis of
671	ovarian cancer: systematic review and meta-analysis of external validation studies <i>BMI</i>
672	Med. 2024:3(1):e000817. doi: 10.1136/bmimed-2023-000817
673	
010	

674	49. Alcázar JL, Pascual MA, Graupera B, et al. External validation of IOTA simple descriptors
675	and simple rules for classifying adnexal masses. Ultrasound Obstet Gynecol.
676	2016;48(3):397-402. doi: 10.1002/uog.15854.
677	
678	50. Kaijser J, Sayasneh A, Van Hoorde K, et al. Presurgical diagnosis of adnexal tumours using
679	mathematical models and scoring systems: a systematic review and meta-analysis. Hum
680	<i>Reprod Update</i> . 2014;20(3):449-62. doi: 10.1093/humupd/dmt059.
681	51 Westwood M. Domoskow D. Long C. et al. Disk sooms to guide asfemal desigions for noonle
002 683	sith suspected ovarian cancer in secondary care: a systematic raviaw and cost affectiveness
684	analysis Health Technol Assess 2018:22(AA):1.26A. doi: 10.3310/bta22440
685	analysis. <i>Health Technol Assess.</i> 2018,22(44).1-204. doi: 10.5510/htta22440.
686	52. Pascual MA. Vancraevnest L. Timmerman S. et al. Validation of ADNEX and IOTA two-
687	step strategy and estimation of risk of complications during follow-up of adnexal masses in
688	low-risk population. <i>Ultrasound Obstet Gynecol.</i> 2024:64(3):395-404. doi:
689	10.1002/uog.27642.
690	
691	53. Timmerman D, Schwärzler P, Collins WP, et al. Subjective assessment of adnexal masses
692	with the use of ultrasonography: an analysis of interobserver variability and experience.
693	<i>Ultrasound Obstet Gynecol.</i> 1999;13(1):11-6. doi: 10.1046/j.1469-0705.1999.13010011.x.
694	
695	54. Moons KG, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic research:
696	application and impact of prognostic models in clinical practice. BMJ. 2009;338:b606. doi:
697	10.1136/bmj.b606.
698	
699	
700	
701	
702	
703	
704	
705	
706	
707	
708	
709	
710	
711	
712	
713	
714	
715	
716	
717	
718	

It is made available under a CC-BY 4.0 International license .

719		
720		
721		
722		
723		
724		
725		
726		
727		
728		
729		
730		
731		
732		
733		
734		
735		
736	Tables	
737		

738 <u>Table 1. Clinical, ultrasound, and histological characteristics of the study</u> population (n=1431). *Median (IQR), or n (%),*

	1.1eutur (1g1t), et it (70)
	Range
Patient age at recruitment (years)	52 (IQR 40-62)
	Range: 18-88
Postmenopausal	745 (52)
Gynecological symptoms during the year preceding inclusion	601 (42)
Bilateral masses	281 (20)
Presence of solid components	730 (51)
Maximum diameter of lesion (mm)	69 (IQR 48-100)
	Range: 9-400
Largest diameter of largest solid component (mm)*	40 (IQR 16-68)
	Range: 2-250
Number of papillary projections	
0	1086 (76)
1	153 (11)
2	49 (3)
3	28 (2)
>3	115 (8)
More than 10 cyst locules	160 (11)
Acoustic shadows	327 (23)
Ascites	120 (8)
CA125 results missing	394 (28)
CA125 (U/mL, if available)	19 (IQR 10-57)
	Range: 1-12000
Colour score of intratumoural flow	-
1: no blood flow	733 (51)
2: minimal blood flow	277 (19)
3: moderate blood flow	239 (17)

It is made available under a CC-BY 4.0 International license .

	4: very strong blood flow	182 (13)
	Histological diagnosis [†]	
	Benign	995 (69)
	Borderline	115 (8)
	Stage II-IV primary invasive	154 (11)
	Secondary metastatic	58 (4)
739 740	IQR: Interquartile range	
741	* specific histological diagnoses are shown in Supplementary Table	S2.
742		
743		
744		
745		
746		
747		
748		
749		
750		
751		
752		
753	Table 2. Calibration in terms of observed over expension	ected ratio based on meta-analysis of data from
	Model	O:E ratio (95% CI)
	SRRisk	1 04 (0 97: 1 12)
	ADNEX without CA125	1.11 (1.04: 1.20)
	ADNEX with CA125	1.18 (1.07: 1.29)
	Two-step without CA125	1.13 (1.05; 1.21)
	Two-step with CA125	1.20 (1.09; 1.32)
754	O:E ratio, observed over expected ratio. Measure of calibration in t	he large (mean calibration) is calculated as the observed risk of
755	having the outcome event in the entire validation dataset divided by	y the average risk predicted by the model. A value >1 indicates
/36 757	that the model is underestimating the average risk. A value <1 means	s that the model is over-estimating the average risk.
758	CI, Confidence Interval, SKRISK, Simple Rules Risk Model, ADNE2	x, Assessment of Different Neoplasias in the adnexa.
750		
759		
761		
762		
763		
764		
765		
766		
767		
768		
769		
770		
771		
772		
773		
774		
775		

It is made available under a CC-BY 4.0 International license .

776		
777		
778		
779		
780		
781		
782		
783		
78/		
785		
786		
787		
700		
700		
709		
790 701		
791		
792		
793 704		
/94 705	Table 3. Polytomous discrimination index (PI	DI) of Assessment of Different NEoplasias in the
195	adnexa (ADNEX), and of the two-step strateg	gy (pooled analysis).
	ADNEX without CA125	0.49 (0.47: 0.53)
	ADNEX with CA125	0.55 (0.51; 0.59)
	Two-step strategy without CA125	0.49 (0.47; 0.52)
	Two-step strategy with CA125	0.55 (0.51; 0.59)
796		
797		
798		
799		
800		
801		
802		
803		
804		
805		
806		
807		
808		
809		
810		
010		
811		
811 812		
811812813		
811812813814		

It is made available under a CC-BY 4.0 International license .

- 0.50

Table 4. Tumor outcome and percentage of missing CA 125 values for all pre-specified subgroups

	Outcome				
Subgroup	Ν	Benign	Malignant	Missing CA125	
Postmenopausal	745	444 (60)	301 (40)	176 (24)	
Premenopausal	686	551 (80)	135 (20)	218 (32)	
Oncology center	817	583 (64)	331 (36)	219 (27)	
Other center	614	412 (80)	105 (20)	175 (28)	
Level of experience of					
ultrasound examiners					
<500 scans	123	102 (83)	21 (17)	41 (33)	
500-5000 scans	650	476 (73)	174 (27)	108 (17)	
>5000 scans	658	417 (63)	241 (37)	245 (37)	
EFSUMB level of					
ultrasound examiners					
Level 1	118	96 (81)	22 (19)	38 (32)	
Level2	884	605 (68)	279 (32)	248 (28)	
Level 3	429	294 (69)	135 (31)	108 (25)	

839 Results are shown as n (%) 840 EFSUMB; European Feder

EFSUMB; European Federation of Societies for Ultrasound in Medicine and Biology

It is made available under a CC-BY 4.0 International license .

Figure 1. Flowchart of the patients included for the analysis.



It is made available under a CC-BY 4.0 International license .

- **Figure 2.** Summary forest plot of area under the receiver operating characteristic curve (AUROC)
- based on meta-analysis of data from 21 centers. CI; Confidence Interval, PI; Prediction Interval.



It is made available under a CC-BY 4.0 International license .

- **Figure 3.** Flexible calibration curves using loess based on meta-analysis. Due to computational
- problems, we divided 13 centers with low sample size or low prevalence of malignancy into four
- groups: Santorso, Foggia, Treviso (group 1); Messina, Carpi, Montebelluna (group 2); Verona,
- Firenze, Padova, Roma (group 3); Bari B, Asti, Bolzano (group 4). The curves were obtained with
- 869 meta-analysis of center-specific curves from eight centers and from the four groups. SRRisk;
- 870 Simple Rules Risk Model, ADNEX; Assessment of Different NEoplasias in the adnexa.

It is made available under a CC-BY 4.0 International license .



It is made available under a CC-BY 4.0 International license .

Figure 4. Decision curves for risk models, Risk of Malignancy Index (RMI), Simple Rules and subjective assessment based on meta-analysis of data from 21 centers. The curves show net benefit at several thresholds between 1% and 50%. A model is clinically useful if it is superior to both treat all and treat none. At risk thresholds below 15%, using RMI at cutoff 200 is worse than treating everyone (i.e., worse than referring all women with an adnexal mass to a gynecological oncology center).



It is made available under a CC-BY 4.0 International license .

Figure 5. Forest plot of area under the receiver operating characteristic curve (AUROC) for

- 884 prespecified subgroups (pooled data). CI; Confidence interval, PI; Predicition interval, EFSUMB;
- 885 European Federation of Societies for Ultrasound in Medicine and Biology.
- 886

	AUROC (95% CI)
Postmenopausal patients (n=745) RMI SRRisk ADNEX without CA125 ADNEX with CA125 Two-step strategy without CA125 Two-step strategy with CA125	0.87 (0.84 to 0.89 0.92 (0.90 to 0.94 0.90 (0.88 to 0.92 0.92 (0.90 to 0.94 0.91 (0.88 to 0.93 0.92 (0.90 to 0.94
Premenopausal patients (n=686) RMI SRRisk ADNEX without CA125 ADNEX with CA125 Two-step strategy without CA125 Two-step strategy with CA125	0.84 (0.80 to 0.88 0.93 (0.90 to 0.95 0.94 (0.91 to 0.96 0.94 (0.91 to 0.96 0.94 (0.91 to 0.96 0.94 (0.91 to 0.96
Oncology center (n=817) RMI SRRisk ADNEX without CA125 ADNEX with CA125 Two-step strategy without CA125 Two-step strategy with CA125	0.85 (0.82 to 0.88 0.92 (0.89 to 0.93 0.90 (0.88 to 0.92 0.92 (0.89 to 0.94 0.90 (0.88 to 0.92 0.92 (0.90 to 0.94
Other center (n=614) RMI SRRisk ADNEX without CA125 ADNEX with CA125 Two-step strategy without CA125 Two-step strategy with CA125	0.88 (0.84 to 0.91 0.93 (0.90 to 0.96 0.94 (0.91 to 0.96 0.94 (0.92 to 0.96 0.94 (0.91 to 0.96 0.94 (0.91 to 0.96
<500 scans performed by examiner (n=123) RMI SRRisk ADNEX without CA125 ADNEX with CA125 Two-step strategy without CA125 Two-step strategy with CA125	0.90 (0.80 to 0.96 0.96 (0.87 to 0.99 0.96 (0.87 to 0.99 0.96 (0.88 to 0.99 0.95 (0.86 to 0.98 0.95 (0.86 to 0.98
500-5000 scans performed by examiner (n=650) RMI SRRisk ADNEX without CA125 ADNEX with CA125 Two-step strategy without CA125 Two-step strategy with CA125	0.89 (0.86 to 0.92 0.94 (0.91 to 0.95 0.93 (0.91 to 0.95 0.94 (0.92 to 0.96 0.94 (0.92 to 0.96 0.94 (0.92 to 0.96
>5000 scans performed by examiner (n=658) RMI SRRisk ADNEX without CA125 ADNEX with CA125 Two-step strategy without CA125 Two-step strategy with CA125	0.84 (0.80 to 0.87 0.91 (0.88 to 0.93 0.90 (0.87 to 0.92 0.91 (0.89 to 0.93 0.90 (0.87 to 0.93 0.92 (0.89 to 0.94
EFSUMB Level 1 (n=118) RMI SRRisk ADNEX without CA125 ADNEX with CA125 Two-step strategy without CA125 Two-step strategy with CA125	0.87 (0.76 to 0.94 0.90 (0.80 to 0.97 0.93 (0.84 to 0.97 0.94 (0.85 to 0.98 0.93 (0.84 to 0.97 0.93 (0.84 to 0.97
EFSUMB Level 2 (n=884) RMI SRRisk ADNEX without CA125 ADNEX with CA125 Two-step strategy without CA125 Two-step strategy with CA125	0.87 (0.84 to 0.89 0.92 (0.90 to 0.94 0.91 (0.89 to 0.93 0.92 (0.90 to 0.94 0.91 (0.89 to 0.93 0.92 (0.90 to 0.94
EFSUMB Level 3 (n=429) RMI SRRisk ADNEX without CA125 ADNEX with CA125 Two-step strategy without CA125 Two-step strategy with CA125	0.86 (0.82 to 0.90 0.94 (0.91 to 0.96 0.94 (0.91 to 0.96 0.95 (0.92 to 0.97 0.94 (0.91 to 0.96 0.95 (0.92 to 0.97
	0.70 0.80 0.90 1.0 AUROC (95% CI)